Drug name - Rozlytrek

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9029356 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US8299057 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Mar, 2029

(6 years from now)

US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(10 years from now)

US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(14 years from now)

CN106167485A GENENTECH INC Acetamidobenzamide, Compositions Containing Acetamidobenzamide And Preparation Method Of Acetamidobenzamide
Feb, 2020

(2 years ago)

CN103923072A GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

CN101754956B GENENTECH INC Substituted Indazole Derivatives Having Activity Of Kinase Inhibitors
Jul, 2028

(5 years from now)

CN101754956A GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

CN103923072B GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

CN104395308B GENENTECH INC N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method
May, 2033

(10 years from now)

CN104395308A GENENTECH INC N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method
May, 2033

(10 years from now)

CN109153669B GENENTECH INC New Crystal Form Of Benzamide Compound
May, 2037

(14 years from now)

CN109153669A GENENTECH INC N - [5 - (3, 5-Difluoro-Benzyl) -1H - Indazol - -3 - Yl]--4-(4-Methyl-Piperazin - -1 - Yl)--2-(Tetrahydropyran - -4 - Ylamino) - Form
May, 2037

(14 years from now)

IN201000870P4 GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

IN281852B GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

IN361050B GENENTECH INC Process For The Preparation Of N-[5-(3-5-Difluoro Benzyl)-1H-Indazol 3 Yl]- 4-(4 Methyl Piperazin -1- Yl) -2- (Tetrahydro Pyran -4- Ylamino) Benzamide
May, 2033

(10 years from now)

IN201409107P4 GENENTECH INC Process For The Preparation Of N [5 (3 5 Difluoro Benzyl) 1H Indazol 3 Yl] 4 (4 Methyl Piperazin 1 Yl) 2 (Tetrahydro Pyran 4 Ylamino) Benzamide
May, 2033

(10 years from now)

EP2855460A1 GENENTECH INC Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
Oct, 2017

(4 years ago)

EP2176231A1 GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

EP2176231B1 GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

EP3290414B1 GENENTECH INC Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3290414A1 GENENTECH INC Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3333166B1 GENENTECH INC Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3333166A1 GENENTECH INC Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3464276A1 GENENTECH INC New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide
May, 2037

(14 years from now)

EP3464276B1 GENENTECH INC New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide
May, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US9616059 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US9085558 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May, 2033

(10 years from now)

US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells Feb, 2035

(12 years from now)

US10561651 GENENTECH INC Methods for treating neuroblastoma Feb, 2035

(12 years from now)

US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May, 2037

(14 years from now)

US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms Jul, 2038

(15 years from now)

Drugs and Companies using ENTRECTINIB ingredient

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; treatment of ros1-positive non-small cell lung cancer; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription
200MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.